For research use only. Not for therapeutic Use.
Potent, orally available and specific PI3K p110β (PI3K beta, PI3Kβ) inhibitor
| Catalog Number | I047577 |
| CAS Number | 2108806-07-9 |
| Molecular Formula | C22H22F3N3O3.2HCl |
| Purity | ≥95% |
| IUPAC Name | 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-morpholin-4-ylbenzimidazole-4-carboxylic acid;dihydrochloride |
| InChI | InChI=1S/C22H22F3N3O3.2ClH/c1-13-15(4-3-5-18(13)22(23,24)25)12-28-14(2)26-20-17(21(29)30)10-16(11-19(20)28)27-6-8-31-9-7-27;;/h3-5,10-11H,6-9,12H2,1-2H3,(H,29,30);2*1H |
| SMILES | CC1=C(C=CC=C1C(F)(F)F)CN2C(=NC3=C(C=C(C=C32)N4CCOCC4)C(=O)O)C.Cl.Cl |
| Reference | RA Rivero, MA Hardwick. Identification of GSK2636771, a potent and selective, orally bioavailable inhibitor of phosphatidylinositol 3-kinase-beta (PI3Kβ) for the treatment of PTEN deficient tumors. Cancer Res. 2012, 72(8 Supplement), 2913.
RM Sanchez et al. Synthesis and structure–activity relationships of 1,2,4-triazolo[1,5-a]pyrimidin-7(3H)-ones as novel series of potent β isoform selective phosphatidylinositol 3-kinase inhibitors. Bioorg. Med. Chem. Lett. 2012, 22(9), 3198-3202.
H Lin. Isoform Selective PI3K-beta Inhibitors. Chin. J. Chem. 2013, 31(3), 299-303. |
